Thermo Fisher to sell Progen primary antibodies

By The Science Advisory Board staff writers

April 30, 2021 -- Gene therapy tools manufacturer Progen Biotechnik has signed a nonexclusive distribution agreement with Thermo Fisher Scientific.

Under the agreement, Thermo Fisher will offer a choice of 371 primary antibodies globally. Among them are top-selling products in biomedical research and development, such as lipid metabolism, cytoskeleton, cell adhesion, and oncology. The antibodies will be available with full service and support from Thermo Fisher.

Progen's portfolio includes over 1,000 primary and secondary antibodies for basic and applied life science research.

Thermo Fisher announces Q1 revenue increase
Thermo Fisher Scientific said that its efforts to help scale vaccine production and support diagnostic testing globally during the COVID-19 pandemic were...
Thermo Fisher to acquire PPD for $17.4B
Thermo Fisher Scientific announced it will acquire clinical research services company PPD for a total cash purchase price of $17.4 billion plus the...
Thermo Fisher debuts KingFisher Apex sample purification system
Thermo Fisher Scientific launched its new KingFisher Apex Purification System, a high-throughput sample purification instrument designed to automate the...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter